XML 33 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 03, 2018
USD ($)
Target
Obligation
Dec. 31, 2019
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock   $ 250,500,000     $ 250,478,974 $ 60,521,729  
Revenues     $ 23,528,853 $ 48,148,275 52,983,433 82,806,171  
Deferred revenue     33,174,765   33,174,765   $ 77,769,629
Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial transaction price $ 252,500,000            
Janssen | License Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Janssen | License Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments $ 1,600,000,000            
Janssen | Research Collaboration and Option Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Number of additional targets for development, regulatory and sales milestone payments | Target 3            
Janssen | Collaboration Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development, regulatory and sales milestones payments $ 1,900,000,000            
Janssen | JNJ-3989 (ARO-HBV) Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payment $ 25,000,000   25,000,000   25,000,000    
Number of distinct performance obligations | Obligation 1            
Revenues     22,200,000 47,900,000 50,900,000 82,500,000  
Contract assets     0   0    
Deferred revenue     33,200,000   33,200,000    
Janssen | ARO-JNJ1              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenues     1,400,000 $ 0 2,100,000 $ 0  
Contract assets     1,300,000   1,300,000    
Deferred revenue     $ 0   $ 0    
JJDC | Common Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Oct. 03, 2018            
Proceeds from the issuance of common stock $ 75,000,000            
Janssen and JJDC | Collaboration and License agreements              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Cash received as due under collaboration agreement $ 175,000,000